Kenya’s Dr. Enoch Kariuki Appointed CFO Of American Biopharmaceutical Company VelosBios Inc

0
622

VelosBios Inc, a clinical-stage biopharmaceutical company committed to developing novel, first-in-class cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), has appointed Dr. Enoch Kariuki as Chief Financial Officer.

Dr. Kariuki joins the company as a highly accomplished finance executive with extensive experience in healthcare strategy, life sciences investment banking, venture capital and business development. Prior to joining VelosBio, Dr. Kariuki served as Senior Vice President, Corporate Development at Synthorx, Inc., where he led the company’s $151 million initial public offering, managed relationships with bankers, sell-side equity analysts and investors, and led the business development process that concluded with the successful sale of Synthorx to Sanofi for $2.5 billion.

Prior to joining Synthorx, Dr. Kariuki was Vice President at H.I.G. Capital, where he led investments into, and served on boards of, several life sciences companies. His roles prior to H.I.G. include Senior Associate at Leerink Partners and Associate Director at UBS Investment Bank. At Leerink and UBS, Dr. Kariuki advised healthcare companies on equity capital financings, mergers and acquisitions, leveraged buyouts, and recapitalizations.

“Enoch brings to VelosBio more than 10 years of experience leading high-performing teams in the private and public sectors. He has a proven track record of success on both the operating and finance sides of our industry, and is precisely the type of high quality individual we are recruiting as we grow our company,” said Dave Johnson, Chief Executive Officer at VelosBio.

“I am excited to join VelosBio at such a dynamic time. The company is developing multiple cancer therapies utilizing its proprietary technology to target ROR1, a novel oncology target, and I look forward to working with Dave and the rest of the senior management and scientific teams to help bring innovative therapies to cancer patients,” said Enoch Kariuki, PharmD, Chief Financial Officer at VelosBio.

Dr. Kariuki completed a Post-Doctoral Fellowship in R&D Strategy and Analytics at Bristol-Myers Squibb and was a practicing pharmacist before transitioning to industry. He holds an MBA from the Tuck School of Business at Dartmouth College and a PharmD from Texas Southern University. He attended Alliance High School in Kenya prior to relocating to America.

Comments

comments